We studied the role of the mitogen-activated protein kinase (MAPK) pathway in the regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in breast tumor MCF-7 cells. We found that addition of a protein kinase C (PKC) activator to MCF-7 cultures prevented TRAILinduced apoptosis, by inhibiting a step downstream of both caspase-8 activation and BID cleavage. TRAILinduced translocation of Bax from cytosol to mitochondria, release of cytochrome c from mitochondria and activation of caspase-9 were all inhibited by PKC activation. PKC-mediated prevention of mitochondrial apoptotic events and apoptosis was found to be dependent on the MAPK pathway. Since TRAIL is a ligand of potential use in antineoplastic clinical trials, our ®ndings may provide relevant information in cancer therapy.
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Keywords: MAPK; TRAIL; apoptosis; MCF-7 cells; mitochondria The lethal eects of diverse anti-tumor agents are often antagonised by cytoprotective signalling systems (Jarvis and Grant, 1999; Makin and Dive, 2001) . In this respect, the subject of apoptosis induction by death receptor ligation and its regulation by protein kinase C has remained in the focus of attention of dierent laboratories (Ruiz-Ruiz et al., 1999; Scadi et al., 1999) . TRAIL, a recently identi®ed member of the tumor necrosis factor (TNF) family with homology to CD95 ligand (Wiley et al., 1995) induces apoptosis in dierent tumor cells upon binding to death-domain containing receptors, TRAIL-R1 and TRAIL-R2 (Ashkenazi and Dixit, 1999) . In contrast, both in vivo and in vitro data indicate that TRAIL is not cytotoxic toward a variety of cultured normal cells (Ashkenazi and Dixit, 1999; Walczak et al., 1999) . However, despite the interest in TRAIL as a potential antitumor agent, very little work has hitherto been done to understand the regulation of TRAIL-induced apoptosis by the intracellular signalling pathways that could be activated in tumor cells (Grith et al., 1998; MacFarlane et al., 2000; Sarker et al., 2001) .
Although contradictory results have been reported regarding the initial steps in TRAIL-apoptosis (Ashkenazi and Dixit, 1999) , more recent data have demonstrated that TRAIL receptors recruit the adapter protein FADD for caspase-8 activation (Sprick et al., 2000) . Apical caspase processing is followed by activation of BID, processing of caspase-9, -3 and -7, cleavage of the nuclear enzyme poly(ADP-ribose)polymerase (PARP) and apoptotic cell death (Grith et al., 1998; MacFarlane et al., 2000) . There is also emerging evidence for the importance of signals from mitochondria during the eector phase of TRAIL-induced apoptotic cell death in breast tumor cells (Srinivasula et al., 2000) .
Serine/threonine PKC could play a survival role in apoptosis triggered by dierent inducers (Illera et al., 1993; Rodriguez-Tarduchy and Lopez-Rivas, 1989) , including CD95 (Ruiz-Ruiz et al., 1999; Scadi et al., 1999) . PKC activates the MAPK pathway (Whitehurst et al., 1992) which in turn can inhibit CD95-mediated apoptosis (Holmstrom et al., 2000; Ruiz-Ruiz et al., 1999) , although MAPK-independent mechanisms may also be operative during PKCmediated inhibition of death receptor-induced apoptosis (Ruiz-Ruiz et al., 1999) . However, the regulation of TRAIL-induced apoptosis seems to be more complex than that induced by CD95L Walczak et al., 2000) . The ®ndings outlined above prompted us to study the role of PKC and MAPK, if any, in regulating TRAIL-induced apoptosis in human breast tumor MCF-7 cells. To evaluate the role of PKC in regulating TRAILinduced apoptosis in human breast cancer MCF-7 cells, we analysed apoptotic events in these cells following the treatment with TRAIL and a PKC activator. Since MCF-7 cells do not express caspase-3 and consequently do not undergo DNA fragmentation during cell death (Janicke et al., 1998) , we determined cell viability and phosphatidylserine externalisation as an estimation of apoptosis. The results show (Figure 1a ) that cell viability declined appreciably in MCF-7 cells in response to TRAIL Oncogene (2002) 21, 4323 ± 4327 and the presence of PKC activator prevented such TRAIL-induced cell death. Furthermore, treatment of MCF-7 cells with phorbol ester markedly inhibited the TRAIL-induced externalisation of phosphatidylserine at the cell surface (Figure 1b ) characteristic of apoptotic cells. We also examined the eect of the PKC activator PDBu on TRAIL-induced activation of caspases by analysing the cleavage of nuclear poly(ADP-ribose) polymerase (PARP), a substrate of eector caspases (Lazebnik et al., 1994) . As shown in Figure 1c , in TRAIL-treated MCF-7 cells the 85 kDa fragment of PARP was observed. However, generation of the 85 kDa fragment by TRAIL treatment was considerable reduced in cells incubated in the presence of PKC activator (Figure 1c ), thereby providing further evidence for a negative role of PKC in the apoptotic signals transduced from TRAIL receptors in MCF-7 cells.
It has been recently described that the inhibition of death receptor-mediated apoptosis in certain cells by PKC activation occurred between death-inducing signaling complex (DISC) formation and caspase-8 activation (Holmstrom et al., 2000; Sarker et al., 2001; Scadi et al., 1999; Tran et al., 2001) . In order to determine the step in the apoptotic pathway triggered by TRAIL that is negatively aected by PKC activation in MCF-7 cells, we examined the eect of PDBu on the processing of caspase-8, the most apical caspase in TRAIL-induced apoptosis in dierent cells including the MCF-7 cell line (MacFarlane et al., 2000; Sprick et al., 2000) . In TRAIL-treated MCF-7 cells, we detected the 55 ± 53 kDa inactive proforms corresponding to both procaspase-8a and -8b as well as the 43 ± 41 kDa fragments corresponding to cleavage of both caspase-8a and -8b between the large and small subunits ( Figure 2a ) which culminates into the release of a large active 18 kDa subunit and the assembly of the active caspases (Medema et al., 1997) . However, in contrast to previous results in other cells (Sarker et al., 2001; Tran et al., 2001) , in MCF-7 cells the processing and activation of caspase-8 upon TRAIL addition was not inhibited by PKC activation (Figure 2a ). Thereafter, we analysed the cleavage of BID as it is the immediate next step after caspase-8 activation in the apoptotic pathway (Scadi et al., 1999) . The results show that in MCF-7 cells, TRAIL induced the cleavage of p22 BID into its p15 fragment (Figure 2b) , as was also shown previously (MacFarlane et al., 2000) and co-treatment of cells with a PKC activator did not cause any signi®cant reduction of TRAIL-induced BID cleavage. These results suggested that PKC hindered TRAIL-mediated apoptosis by playing a role downstream of caspase-8 activation and BID cleavage in MCF-7 cells.
A mitochondrial pathway has been implicated in death receptor-mediated apoptosis in MCF-7 cells (Scadi et al., 1998) . This pathway appears to be essential for TRAIL-induced apoptosis in MCF-7 cells as overexpression of either Bcl-X L or Bcl-2 was reported to inhibit TRAIL-induced cytochrome c release from mitochondria and apoptosis in these cells Figure 1 Treatment with a PKC activator inhibited TRAILmediated apoptosis in MCF-7 cells. (a) Human breast cancer MCF-7 cells, maintained in culture in RPMI 1640 medium containing 10% FCS and 1 mM L-glutamine, at 378C in a humidi®ed 5% CO 2 /95% air incubator, were treated for 24 h with 250 ng/ml TRAIL (PreproTech ECLTD, UK) following 1 h preincubation with or without 20 ng/ml phorbol-12,13-dibutyrate (PDBu, Sigma, Poole, UK) Cell viability was assayed by crystal violet staining as described previously (Ruiz-Ruiz et al., 2000) . Results are representative of three independent experiments. (b) MCF-7 cells were treated for 13 h with 250 ng/ml TRAIL following 1 h preincubation with or without 20 ng/ml PDBu. Phosphatidylserine (PS) exposure on the surface of apoptotic cells was detected by¯ow cytometry after staining with Anexin-V-FLUOS (Roche Molecular Biochemicals). Flow cytometry was performed on a FACScan cytometer using the Cell Quest software (Becton Dickinson, Mountain View, CA, USA). Error bars represent standard deviation (s.d.) from two independent experiments. (c) Cleavage of PARP was determined by Western blot. Cells were incubated for 1 h in the absence or presence of 20 ng/ml PDBu before treatment with or without 250 ng/ml TRAIL for 8 h. Following detachment with RPMI/EDTA, cells (5610 5 ) were washed with phosphate-buered saline (PBS) and lysed in 20 ml sample buer (50 mM Tris-HCl pH 6.8, 6 M urea, 6% 2-mercaptoethanol, 3% SDS, 0.003% bromophenol blue). Cell samples were sonicated and proteins were resolved on SDSpolyacrylamide minigels and detected as previously described (Sarker et al., 2001) . Blots were probed with rabbit polyclonal antiserum against PARP purchased from Roche Molecular Biochemicals, Germany. The 116 kDa PARP and its 85 kDa cleavage product are indicated by arrows. Results are representative of three independent experiments Inhibition of TRAIL-induced apoptosis by MAPK activation M Sarker et al (de Almodovar et al., 2001; Srinivasula et al., 2000) . We therefore studied the localisation of mitochondrial cytochrome c in MCF-7 cells and found that cytochrome c was released from mitochondria into the cytosol of these cells upon TRAIL treatment (Figure 3a) . Interestingly, the data of Figure 3a also show that as a result of PKC activation TRAILinduced release of mitochondrial cytochrome c into the cytosol was markedly inhibited. Altogether, our results suggest that in MCF-7 cells the activation of PKC suppresses TRAIL-induced apoptosis at some step between BID cleavage and the release of cytochrome c from mitochondria. Translocation of Bax from the cytosolic compartment to the mitochondria has been reported to cooperate with BID activation in the release of cytochrome c from mitochondria (Eskes et al., 2000) . We therefore investigated the localisation of Bax in MCF-7 cells treated with TRAIL and observed the loss of Bax from the cytosol in response to TRAIL treatment and its translocation to a mitochondriacontaining fraction (Figure 3a) . Interestingly, this translocation was clearly prevented when TRAILtreated cells were simultaneously exposed to PKC activator. Our observation of PKC-driven inhibition of Bax translocation in this cell line is of interest because it helps to envisage that in MCF-7 cells Bax translocation to mitochondria rather than BID cleavage could be the limiting step in the release of cytochrome c from mitochondria upon TRAIL receptor activation. Moreover, in contrast to what was observed in other cells (Holmstrom et al., 2000; Sarker et al., 2001; Scadi et al., 1999; Tran et al., 2001) , in the case of TRAIL-triggered apoptosis in MCF-7 cells, activated PKC exerts its inhibitory action downstream of caspase-8 activation and BID cleavage but upstream of cytochrome c release. These apparently dierent data may be attributed to the absence of caspase-3 in MCF-7 cells (Janicke et al., 1998) . In cells expressing caspase-3, the activation of executioner caspase-3 in response to cytochrome c release may activate caspase-6 which in turn activates caspase-8 (Slee et al., 1999) . Furthermore, the cleavage of BID in T cells during drug and radiation-induced apoptosis was shown to be dependent on caspase-3 activation Figure 3 TRAIL-induced mitochondria-related events were prevented by PKC activation. Cells were treated with or without 250 ng/ml TRAIL for 8 h following a preincubation period of 1 h with or without 20 ng/ml PDBu. (a) Levels of Bax and cytochrome c in cytosolic and membrane fractions were determined by Western blot. Following treatment, cells were lysed and cytosolic proteins were separated from mitochondria as previously described (Sarker et al., 2001) . Protein extracts (40 mg) were mixed with Laemmli buer and resolved on SDS ± 12% PAGE minigels. Blots were probed with mouse anti-cytochrome c mAb for the determination of cytochrome c release from mitochondria or with mouse anti-Bax mAb for detection of translocation of Bax from cytosol to mitochondria. Both of these antibodies were obtained from Pharmingen (San Diego, CA, USA). Cytosolic blots were also probed for a-tubulin with monoclonal antibody to alpha-tubulin from Sigma (Poole, UK) as a control for protein loading. Mitochondrial Bcl-2 protein was undetectable in the cytosolic samples (not shown). Blots from the mitochondria-containing fraction were also probed for the presence of the mitochondrial marker Bcl-2 with monoclonal antibody anti-Bcl-2 (DAKO, Denmark), as control for protein loading. (b) Caspase-9 activation was assessed by the generation of the 37 kDa fragment of cleaved procaspase-9 using a rabbit polyclonal antibody to caspase-9 p37 fragment obtained from New England BioLabs Inc. (Beverly, MA, USA). a-tubulin serves as a control for protein loading. Results are representative of at least two independent experiments (Slee et al., 2000) . Moreover, the impaired activation of caspase-8 in cells from APAF-1(7/7) and CASP9(7/ 7) mice Yoshida et al., 1998) provided compelling evidence of late caspase-8 activation downstream of cytochrome c release. Therefore, the PKC-mediated prevention of TRAIL-induced caspase-8 activation and BID cleavage observed previously in caspase-3-expressing cells (Sarker et al., 2001; Tran et al., 2001 ) might be a consequence of a block in the feedback ampli®cation loop through the mitochondria.
Once released into the cytosol, cytochrome c interacts with Apaf-1 and dATP and induces the processing and activation of procaspase-9, with the resultant activation of downstream caspases that leads to apoptosis (Li et al., 1997) . We found that TRAIL induced the activation of caspase-9 in MCF-7 cells (Figure 3b ) in agreement with a previous report (MacFarlane et al., 2000) . However, in the presence of PKC activator, the processing of caspase-9 was clearly inhibited (Figure 3b ). Our present data in breast tumor MCF-7 cells point out to a central role of mitochondria-regulated events in TRAIL-induced apoptosis and are in agreement with recent reports showing the inhibition of TRAIL-mediated apoptosis by overexpression of mitochondrial antiapoptotic Bcl-X L and Bcl-2 proteins (de Almodovar et al., 2001; Srinivasula et al., 2000) . Hence in breast cancer MCF-7 cells, PKC most possibly plays a survival role through the abrogation of the TRAIL-activated mitochondrial events that otherwise would lead to activation of the apoptotic machinery and cell death.
The MAPK pathway plays a survival role and inhibits CD95-mediated apoptosis (Holmstrom et al., 2000; Ruiz-Ruiz et al., 1999; Yeh et al., 1998) . Based on these results, we have evaluated the role of MAPK activation in PKC-induced prevention of TRAILmediated cytochrome c release, Bax translocation and apoptosis by using PD 098059, a speci®c inhibitor of MEK-1 activation (Alessi et al., 1995) . It is evident from Figure 4a that the PKC-mediated inhibition of Bax translocation and the corresponding prevention of cytochrome c release from mitochondria were completely abrogated in TRAIL-treated MCF-7 cells when the cells were co-incubated with the MEK-1 inhibitor. Furthermore, it is also interesting that in the presence of PD 098059, there was an increased eect of TRAIL on both the release of cytochrome c from mitochondria and the loss of Bax from the cytosol of MCF-7 cells (Figure 4a) , suggesting a certain role of basal MAPK activity in counteracting the apoptotic action of TRAIL in these cells. Furthermore, the prevention by PKC activation of viability loss (Figure 4b ) and phosphatidylserine externalisation (Figure 4c ) in TRAIL-treated cultures of MCF-7 cells, were clearly reduced in the presence of PD 098059. Altogether, our results indicate that in MCF-7 cells the activation of the MAPK pathway by PKC can be envisaged to be crucial for the observed abrogation of TRAIL-induced cytochrome c release and Bax translocation as well as critical for the associated survival eect in MCF-7 cells. The present ®ndings may have a direct bearing on cancer therapy as certain breast tumor cells possess increased MAPK activities (Sivaraman et al., 1997) and therefore, treatment of these tumors with inhibitors of the MAPK pathway could sensitise them to soluble TRAIL.
